Experts in Infectious Diseases to House Leaders: Address Antimicrobial Resistance
Trish Perl, MD, FIDSA, spoke on behalf of the Infectious Diseases Society of America at Thursday’s House Budget Committee roundtable on the threats of antimicrobial resistance.
House Appropriations Bill Misses the Mark on ID Programs
The House FY 2025 Labor, Health and Human Services and State and Foreign Operations appropriations bills largely flat fund antimicrobial resistance programs at FY 2024 levels even as AMR grows as a serious public health threat.
IDSA Advocacy Delivers Significant Victory for ID in Proposed Medicare Fee Schedule
The Centers for Medicare and Medicaid Services released its calendar year 2025 Medicare Physician Fee Schedule Proposed Rule July 10, including a new “add-on” code for infectious diseases developed and advocated for by IDSA.
IDSA Releases New Guidelines for Complicated Intra-Abdominal Infections
The Infectious Diseases Society of America has released new guidelines on complicated intra-abdominal infections in children, adults and pregnant people.
IDSA and HIVMA Response to New CDC Guidelines on Doxycycline as Post-Exposure Prophylaxis
IDSA and HIVMA welcome the Centers for Disease Control and Prevention’s guidelines for implementing doxycycline as post-exposure prophylaxis, or doxy PEP, to prevent sexually transmitted infections.
IDSA and HIVMA Response to Uganda Court Decision on the Anti-Homosexuality Act
IDSA and HIVMA are disappointed and alarmed that Uganda’s Constitutional Court upheld the Anti-Homosexuality Act criminalizing LGBTQ individuals and their right to organize, educate and advocate. We are deeply concerned by the impact of the law on Uganda’s HIV response and for people with HIV and vulnerable to HIV in the country.
IDSA Reacts to ID Funding Proposals in the President’s FY2024 Budget Request
IDSA is encouraged that the president’s FY 2025 Budget Request proposes deeper investments in several key IDSA priorities, including the CDC Antibiotic Resistance Solutions Initiative (to prevent, detect, track and contain antimicrobial resistance) and the National Institute of Allergy and Infectious Diseases, though IDSA is advocating for even larger funding increases for these priorities.
IDSA Responds to Funding for ID Programs in FY2024 Health and Foreign Operations Bills
The legislation averts proposed cuts to the National Institute of Allergy and Infectious Diseases and other ID/HIV programs. The bill also includes a one-year extension of expired President’s Emergency Plan for AIDS Relief provisions. IDSA continues to urge Congress to provide sufficient funding in FY 2025 for ID and HIV programs.
Cardiovascular Infection on the Rise: New Multisociety Statement Defines Appropriate Use of PET/CT and SPECT/CT for Evaluation
As use of prosthetic heart valves and implanted cardiac devices has increased, so too has the incidence of cardiovascular infection. While accurate diagnosis of this condition is critical for guiding treatment decisions that can prevent death and significant morbidity, current assessment strategies have proven insufficient.
IDSA Supports CDC Guidance on Preventing Respiratory Virus Spread
As we enter the fourth year since the first detection of SARS-CoV-2, much has changed. Over 95% of Americans have some degree of immunity either from prior infection, vaccination or both.
IDSA Response to CDC’S Spring 2024 COVID Vaccine Recommendation
Infectious diseases experts strongly encourage an additional COVID-19 vaccine in spring 2024 for people 65 years of age and older as recommended by the Centers for Disease Control and Prevention.
LEAP Fellowship Program Builds ID-Public Health Partnerships
The Leaders in Epidemiology, Antimicrobial Stewardship and Public Health (LEAP) Fellowship program is an effective model for partnerships between early-career infectious diseases physicians and public health departments, according to new research published in Clinical Infectious Diseases.